Invitation to become a host country of the 3rd International Forum of Pharmaceutical Inspectorates (IFPI-2026)
The IFPI Organizing Committee invites you to participate in holding the 3rd International Forum of Pharmaceutical Inspectors (IFPI-2026).
The 1st International Forum of Pharmaceutical Inspectorates, held in Dubai in 2024, and the 2nd Forum, held in Abu Dhabi in 2025, demonstrated the high relevance of this event for the global GMP community. IFPI provides an opportunity for national regulatory authorities, pharmaceutical inspectors, and pharmaceutical industry experts to exchange best practices, work together to further develop and deepen regulatory cooperation and information exchange, promote regulatory convergence, and raise global standards for pharmaceutical inspections.
In accordance with the decision taken by the IFPI 2025 Organizing Committee, the venue for the IFPI Forum in 2026 will be selected on the basis of proposals from participating countries.
Hosting the event will provide the following benefits to the host country:
Active participation in shaping the agenda of the 3rd International Forum of Pharmaceutical Inspectorates;
Opportunity to present the features and achievements of your country’s pharmaceutical industry regulatory system;
Opportunity to showcase the achievements of national pharmaceutical companies;
Strengthening your image and expanding opportunities for multilateral cooperation in the field of regulation, as well as stimulating international cooperation with enterprises (B2G);
Exchanging knowledge and experience with leading international experts in the field of pharmaceutical inspections.
If you are interested in your country becoming the venue for this significant event, we invite you to familiarize yourself with our selection criteria and fill out the form. Your initiative will strengthen business ties, broaden the horizons of cooperation, and may become the key to successfully organizing and hosting the event at the highest level.
If you are interested, please send an official letter in free form to the Organizing Committee of the Forum expressing your willingness to act as a host by e-mail: info@ifpi-forum.com no later than January 20, 2026. As a next step, please fill out the attached form and send it by e-mail: info@ifpi-forum.com by January 30, 2026.
International Forum of Pharmaceutical Inspectorates
is the main platform for professional dialogue, exchange of experience, and shaping the future of the pharmaceutical industry.
The Forum aims at developing cooperation between the National Regulatory Authorities of other countries in regulation of medicinal products and GMP inspections, in particular, in the Global South and Eurasia.
Uniform standards guarantee quality
Ensuring access to high-quality, safe and effective medicines by developing a pharmaceutical inspection system, unifying standards and strengthening the professional capacity of inspectors.
Professional Background: Over 40 years of experience in pharmaceutical regulatory affairs. 23 years as Head of GMP at the TGA Australia. Former Chairman of PIC/S. Global GMP Consultant assisting regulatory authorities worldwide in achieving PIC/S membership.
Key Achievements: Assisted 15 GMP regulatory authorities obtain PIC/S membership over the past 18 years (the most recent was JFDA, Jordan which became a PIC/S member on 1 January 2026). Currently assisting 6 GMP regulatory authorities prepare for either pre-accession or full accession to PIC/S.
Awards & Recognition: US FDA Commissioner's Award (initiated ICH Q7A). John Martin Memorial Award (RACI, Australia). ISPE Joe Phillips Award for professional achievement.
Khamusi Philip Mutoti
Current Position: Senior Regulatory Affairs Associate, Roche Holding AG
Professional Background: A highly accomplished regulatory scientist with a decade of specialized experience in the evaluation, policy formulation, and registration of Biological Medicines. Founder and inaugural Chairperson of the African Blood Regulatory Forum (ABRF-TC) — a premier Continental Technical Working Group under the African Medicines Regulatory Harmonisation (AMRH) initiative. Spearheaded the historic unification of blood and blood product regulations across South Africa and the wider African continent. This leadership has been pivotal in advising the African Medicines Agency (AMA) and AUDA-NEPAD, driving the creation of harmonized technical guidelines, innovative regulatory pathways, and reliance frameworks across Member States. A trusted voice on expert committees, bridging complex biological assessment with continental healthcare strategy to ensure equitable access to quality-assured, safe, and affordable blood products for all African citizens. Over the past 17 years, significant contributions have been made to the advancement of global health regulation through peer-reviewed publications and high-level international representation.
Key Publications & Research: Published definitive frameworks on biosimilar registration and blood product implementation in the GaBI Journal and Research Square. Authored a landmark 10-country sub-Saharan haemovigilance study.
Presentations & Speaking Engagements: Featured speaker at the WHO's 18th International Conference of Drug Regulatory Authorities (ICDRA) in Dublin. Featured speaker at the 1st International Symposium on Streptococcus agalactiae Disease in Cape Town.
Pantelia Gkoura
Current Position: Founder & Managing Director, CONSILIUM LPG Consulting Services S.M.P.C.Chemist, TQM MBA. Senior Pharmaceutical Regulatory Expert.
Professional Background: 2022 – Present: Founder & Managing Director, CONSILIUM LPG Consulting Services S.M.P.C., Greece. Consulting services on GMP/GDP compliance, regulatory systems strengthening, quality management systems, and market surveillance of pharmaceutical enterprises. International Consultant for pharmaceutical regulatory systems: Jordan (JFDA / IFC – World Bank Group): PIC/S accession preparation, WHO GBT alignment, QMS development, SOPs, and inspector training. Pakistan (DRAP / WHO): Strengthening market surveillance and control systems for substandard and falsified medical products. UAE (Dubai Regulatory Authority): GMP/GDP compliance, inspection systems, and QMS strengthening.
2014 – 2021: Head of Production & Distribution Control Division (GMP/GDP Inspectorate), EOF Greece.
2011 – 2013: Head of Market Surveillance Section, EOF Greece.
Key Achievements & Experience: More than 20 years of experience in GMP/GDP inspections, market surveillance, and pharmaceutical regulatory systems strengthening.
Successfully supported PIC/S accession and ISO/IEC 17020 accreditation of the EOF GMP/GDP Inspectorate.
Contributed to the EU–US FDA Mutual Recognition Assessment, confirming the equivalence of the Greek GMP inspection system.
Extensive experience supporting WHO, PIC/S, and EU regulatory alignment in Europe and the Middle East.
Expert in quality management systems (ISO 9001, ISO 17020, ISO 13485), risk-based post-marketing surveillance, and supply chain integrity.
Certified Trainer for Adults and External Assessor for Medical Devices Accreditation. Official representative of the Greek Ministry of Health and EOF in several European and international regulatory bodies.
Dr. Vee (Vasiliki) Revithi
Current Position: Senior Consultant to Regulatory Authorities (GMDP Inspectorates)
Professional Background: About 40 years' experience in EOF (Medicines Agency of Greece), 5 years' in the Pharmaceutical Industry (Roche, Switzerland). Since 2018, a self-employed International Consultant to Regulatory Agencies to achieve PIC/S membership and WHO GBT ML3 to 4.
Pharmaceutical Regulatory Expert with 37 years of experience, 12 of them as Head of GMDP at EOF, the Medicines Authority of Greece. Participated for more than 25 years in EU meetings in Brussels and EMA, involved in many EU Regulations preparation.
Leadership in the implementation of a Quality System according to EU, PIC/S and ISO17020 in the Greek GMDP Inspectorate and the accession of EOF to PIC/S in 2002. Represented EOF/Greece and has been a member of the PIC/S Executive Bureau (Chair of Compliance Group, monitoring new applications at PIC/S). Involvement in several State Inspectorates' PIC/S and EU assessment Teams (US FDA, Romania, Austria, Cyprus, Iran, Uganda, Armenia, UNICEF) and at the EU-Japan MRA. Performed GMP inspections with EDQM and WHO Prequalification Program in India and China and in missions as "Assistance to CFDA" project by WHO/Global Fund. Worked for the Industry at Roche, Switzerland in External Relations Europe.
Key Achievements & Experience: Global GMP Consultant assisting regulatory authorities in obtaining PIC/S membership, including Armenia (2012), Turkey (2013), Jordan (2020-2025), China (2019, 2024), UAE (2026).
Consultant for the successful assessment by WHO GBT on all functions of a regulatory authority.
Liang Zhao
Current Position: Senior Vice President, BioEngine, China
Professional Background: Has dedicated 25 years to the industrialization of protein drugs and viral biologics based on cell culture technology. In particular, he accumulates extensive experience in the efficient industrial production technology of biopharmaceuticals and viral vaccines, the medium and process development and large-scale manufacturing of the key raw materials—serum-free culture media, as well as the regulation of critical quality attributes of products.
As a lead, he has presided over multiple key projects—such as the National 863 Program, NSFC grants, and Shanghai Science and Technology Commission initiatives—he successfully addressed critical scale-up and engineering challenges, accelerating the industrialization of related bioproducts.
Key Achievements & Experience: Contributed to regulatory infrastructure by serving as a principal drafter of China’s first two group quality standards for serum free media (T/SBIAORG 0002 2022 & T/SBIAORG 0003 2022), establishing the guides for cell culture medium quality
Wayne Matheuw Müller
Current Position: GMP Expert, Inspector with South African Health Products Regulatory Authority (SAHPRA)
Professional Background: GMP Expert. Inspector with South African Health Products Regulatory Authority (SAHPRA) responsible for conducting national and international inspections. Chair of the GMP Technical Committee of African Medicines Regulatory Harmonization (AMRH). Chair of the GMP Technical Committee focusing on Vaccine, Biological and API manufacture under the auspices of the African Medicines Regulatory Harmonization, which is transitioning to the African Medicines Agency. Member of ZAZIBONA Inspection Team. Member of WHO PQ inspection team. Member of WHO RSS team. Member of various workgroups e.g. Annex 1 Implementation team, Unique Facility Identifiers, Contamination and Cross Contamination in Shared facilities, Anti-Microbial Resistance and Waste Treatment.
Dr. Heba Bahaa
Current Position: Manager of Biological Inspection Administration at Egyptian Drug Authority (EDA). Chairman of GMP subcommittee of vaccine at African Medicine Agency.
Professional Background: Over 16 years of experience in pharmaceutical regulation and GMP inspections, with extensive expertise in biological products, vaccines, blood products, biosimilars, and plasma-related facilities.
Currently serving as Manager of the Biological Inspection Administration at the Egyptian Drug Authority since 2024.
Previously held several regulatory and leadership positions within EDA, including Chairman of the Technical Office (2022−2024).
Active contributor to WHO regulatory initiatives and African Medicines Regulatory Harmonization (AMRH) activities, including inspector training, quality systems development, and risk-based inspection programs.
Key Achievements & Experience: Played a significant role in strengthening pharmaceutical regulatory systems at both national and international levels. Contributed to the development and revision of regulations and guidelines related to radiopharmaceuticals, plasma apheresis centers, biosimilars, vaccines, and blood products in Egypt.
Internationally, collaborates with WHO and AMRH initiatives as a WHO GMP Advisor and focal point for biological inspections during WHO accreditation activities.
Serves as Chairperson of the Vaccine GMP Sub-Technical Committee at AMRH (AMA), leading initiatives for guideline harmonization, inspection capacity building, and regulatory strengthening across African countries.
Pharmaceutical companies have the opportunity to showcase their products at the exhibition as part of the Forum
In 2025, leading pharmaceutical companies took part in the exhibition. Developments in the field of innovative drugs, biosimilars and generics were presented.